Cedar Mountain Advisors’s Oncolytics Biotech ONCY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.37K Hold
5,651
﹤0.01% 664
2026
Q1
$4.8K Hold
5,651
﹤0.01% 669
2025
Q4
$4.94K Hold
5,651
﹤0.01% 319
2025
Q3
$7.91K Hold
5,651
﹤0.01% 283
2025
Q2
$4.37K Hold
5,651
﹤0.01% 277
2025
Q1
$3.11K Hold
5,651
﹤0.01% 274
2024
Q4
$5.16K Hold
5,651
﹤0.01% 256
2024
Q3
$4.92K Hold
5,651
﹤0.01% 247
2024
Q2
$5.59K Hold
5,651
﹤0.01% 223
2024
Q1
$5.99K Hold
5,651
﹤0.01% 214
2023
Q4
$7.63K Hold
5,651
﹤0.01% 197
2023
Q3
$12.3K Hold
5,651
﹤0.01% 163
2023
Q2
$14.7K Hold
5,651
﹤0.01% 136
2023
Q1
$6.78K Hold
5,651
﹤0.01% 189
2022
Q4
$9.21K Hold
5,651
﹤0.01% 166
2022
Q3
$7K Hold
5,651
﹤0.01% 186
2022
Q2
$6K Hold
5,651
﹤0.01% 204
2022
Q1
$9K Hold
5,651
﹤0.01% 183
2021
Q4
$8K Hold
5,651
﹤0.01% 198
2021
Q3
$12K Hold
5,651
﹤0.01% 151
2021
Q2
$16K Hold
5,651
0.01% 132
2021
Q1
$22K Hold
5,651
0.01% 125
2020
Q4
$13K Hold
5,651
﹤0.01% 155
2020
Q3
$10K Hold
5,651
﹤0.01% 161
2020
Q2
$11K Hold
5,651
﹤0.01% 143
2020
Q1
$8K Hold
5,651
﹤0.01% 135
2019
Q4
$27K Buy
+5,651
New +$6.38K 0.01% 92

Other funds holding ONCY

Cedar Mountain Advisors's ONCY Position: Q2 2026 in Review

Cedar Mountain Advisors held its Oncolytics Biotech (ONCY) position steady in Q2 2026 at 5,651 shares worth $5.37K. The position accounts for ﹤0.01% of the portfolio, ranked #664.

Cedar Mountain Advisors first reported a position in ONCY in Q4 2019 and has held it in 27 quarters since. The position peaked at $27K in Q4 2019. 24 funds tracked by Wall St. Rank hold ONCY as of Q2 2026.

  • Cedar Mountain Advisors held 5,651 shares of Oncolytics Biotech worth $5.37K as of Q2 2026.
  • Cedar Mountain Advisors left its Oncolytics Biotech share count unchanged in Q2 2026.
  • Oncolytics Biotech made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #664 holding.
  • Cedar Mountain Advisors first reported a position in Oncolytics Biotech in Q4 2019 and has held it in 27 quarters since.
  • Cedar Mountain Advisors's Oncolytics Biotech position peaked at $27K in Q4 2019.
  • 24 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.